Suven Life Sciences has announced a strong scientific showcase at the upcoming SLEEP-2026 Annual Meeting in Baltimore, where it will present three posters highlighting the clinical progress of its investigational CNS therapy Samelisant.

The clinical-stage biopharmaceutical developer confirmed that its presentations will be featured at the 40th annual meeting of the Associated Professional Sleep Societies (APSS), LLC— a joint initiative of the American Academy of Sleep Medicine and the Sleep Research Society.

The event runs from June 14–17, 2026, and is expected to draw thousands of clinicians, researchers, and industry participants from around the world.

Samelisant (SUVN-G3031), an investigational compound targeting CNS sleep-wake regulation, will be the centerpiece of Suven’s scientific presence.

The company will present data spanning Phase 2 efficacy results in excessive daytime sleepiness (EDS), clinical trial design for cataplexy in Type 1 narcolepsy, and the Phase 3 development strategy for its lead AWAKE study in narcolepsy patients.

Beyond the formal presentations, Suven’s scientific leadership team will also engage in multiple meetings with Phase 3 investigators, key opinion leaders, and potential global partners—signalling continued momentum toward late-stage clinical development and strategic collaborations.

With its latest data package heading to one of the world’s most influential sleep medicine conferences, Suven is positioning Samelisant as a key contender in the evolving narcolepsy treatment landscape.